<DOC>
	<DOCNO>NCT01516073</DOCNO>
	<brief_summary>This multi-center , randomize , placebo-controlled parallel-group study evaluate nebulized fluticasone propionate ( FP ) dose response adult subject partly control uncontrolled asthma . Individual participation approximately 16 week , include 12 week double-blind treatment .</brief_summary>
	<brief_title>12-Week Study Adult Subjects With Asthma</brief_title>
	<detailed_description>The primary outcome measure FEV1 ( Forced Expiry Volume 1 second ) secondary outcome measure Peak Expiratory Flow Rate ( PEFR ) , Asthma Control Questionnaire ( ACQ ) , nighttime awakening reduce medication usage .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>1 . A signed date write informed consent form prior conduct study procedures 2 . Males females 18 60 year old . 3 . Nonsmoker least 1 year prior Visit 1 , smoke history 10 packyears . 4 . Ability understand comply protocol requirement ( include completion daily PEFR , PFT ACQ ) , instruction protocolstated restriction . 5 . Women childbearing potential ( WOCBP ) must negative pregnancy test screen visit . WOCBP include : female experience menarche postmenopausal ( define amenorrhea least 12 consecutive month ) , undergone surgical sterilization ( hysterectomy , bilateral oophorectomy , bilateral tubal ligation ) . Women use acceptable contraceptive medication device prevent pregnancy practice abstinence partner sterile ( e.g. , vasectomy ) consider WOCBP . WOCBP must agree avoid become pregnant duration study use adequate contraception study entry throughout trial . Examples adequate contraception include follow : Norplant Medroxyprogesterone acetate injection Oral contraception Doublebarrier method ( e.g. , condom spermicide ) Abstinence , one WOCBP advise notify Investigator change pregnancy status change contraceptive use . 6 . Agreement subject abide study protocol restriction . 1 . Past present disease , exclude asthma , judge investigator , may place subject increase risk complication , interfere study participation , confound study objectives These disease include , limited cardiovascular disease , malignancy , gastrointestinal disease , hepatic disease , diabetes type I uncontrolled diabetes , type II , renal disease , haematological disease , neurological disease , endocrine disease pulmonary disease ( include , confine chronic bronchitis , emphysema , bronchiectasis , COPD , eosinophilic bronchitis pulmonary fibrosis ) . 2 . Clinically significant abnormality safety laboratory analysis screening ( Visit 1 ) deem exclusionary Investigator . 3 . An upper low respiratory tract infection within 4 week Visit 1 prior Visit 2 4 . A history hypersensitivity study drug component , include albuterol rescue medication . 5 . History illegal drug alcohol abuse within past 5 year . 6 . Pregnant lactating woman . 7 . Use investigational drug device within 30 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>partially control</keyword>
	<keyword>uncontrolled</keyword>
</DOC>